Brokerages Anticipate ESSA Pharma Inc (EPIX) to Post ($0.43) Earnings Per Share
Shares of ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price target of $21.00 for the company and are anticipating that the company will post ($0.43) EPS for the current quarter, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 101 out of 255 based on the ratings given to its competitors.
Separately, Zacks Investment Research upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Monday, August 20th.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings data on Tuesday, August 14th. The company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.74) by $0.24. Analysts expect that ESSA Pharma will post -2.6 EPS for the current year.
A hedge fund recently bought a new stake in ESSA Pharma stock. DRW Securities LLC acquired a new stake in ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 33,857 shares of the company’s stock, valued at approximately $128,000. DRW Securities LLC owned 0.59% of ESSA Pharma as of its most recent SEC filing. 60.77% of the stock is currently owned by institutional investors and hedge funds.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
See Also: How is inflation measured?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.